RESPIRATORY
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
|
|
As initiation therapy for group D with a history of asthma or exacerbations
|
|
|
As follow-up therapy in all ABCD groups in bronchodilator monotherapy patients with history or findings of asthma and for combination LABA/LAMA patients with exacerbations with eos levels ≥100 cells/µL respectively
|
|
|
As follow-up therapy for patients in the ABCD group with ≥ 2 moderate exacerbations per year or at least 1 severe exacerbation requiring hospitalization 1 year previously
|
|
|
All true
|
Detailed explanation-1: -Patients’ airflow limitation with a post-bronchodilator forced expiratory volume/forced vital capacity (FEV1/FVC) <0.7 is further classified based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines as either GOLD 1 (mild), GOLD 2 (moderate), GOLD 3 (severe), or GOLD 4 (very severe).
Detailed explanation-2: -Non-Pharmacologic Therapy: The GOLD guidelines recommend smoking cessation, flu and pneumococcal vaccinations for patients with COPD in Groups A through D. Vaccinations are one way to reduce exacerbations, which are known to cause a more rapid decline in lung function, increased morbidity and mortality.
Detailed explanation-3: -ICS together with LABA or LABA/LAMA reduces the risk of exacerbations in COPD. ICS, however, do have side effects where an increased risk of pneumonia is probably the most clinically important one. The indication of using ICS in COPD is stronger if the patient has concomitant asthma and or increased B-Eos levels.
Detailed explanation-4: -What Are the Stages of COPD? Stage I (Early) Stage II (Moderate) Stage III (Severe) Stage IV (Very Severe) 29-Jul-2021